(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Why some African countries are prone to military takeovers - 2Israel approves death penalty law for Palestinians convicted of attacks
- 3Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- 4Feeling wonder every day improves our health. Here’s how to do it.
- 5Astronauts head home early after medical issue
- Top notch Feasting: A Manual for Worldwide Acclaimed Eateries
- NASA releases stunning first images of Earth taken by the Artemis II astronauts
- 'Yellowstone' made him a fan favorite. His biggest role isn't the one you see.
- Father and son spending Christmas together after health scares
- Higher cost, worse coverage: Affordable Care Act enrollees say expiring subsidies will hit them hard
- 10 Moving Design Frill for Summer 2023
- The 10 Most Famous Works of art Ever
- 4 Family SUVs: Joining Solace and Style
- 'I was diagnosed with incurable brain cancer on holiday'
